There is growing pressure for therapeutics to demonstrate meaningful health benefits beyond the traditional weight loss efficacy metrics. For example, body composition assessments are increasingly used as evidence of “quality” weight loss, demonstrating that weight loss comes preferentially from fat loss.
At the centre of obesity, type 2 diabetes and various other metabolic diseases are adipose tissue excess (adiposity) and adipose tissue dysfunction (adiposopathy). Previously thought of as a passive energy store, adipose tissue is now recognized as a dynamic, metabolically active endocrine organ with many important functions. Adipose tissue expansion, distribution and dysfunction affect overall metabolic health, individual tissue function and a range of related conditions.
In this webinar, the featured speakers will discuss and explore adipose tissue function and dysfunction, addressing key questions including:
What is currently understood about adipose tissue biology and how it changes in disease states such as obesity and type 2 diabetes?
How does adipose tissue change with weight loss and treatment? How are volumetric reduction, spatial distribution and plasticity/composition changes linked to metabolic improvements, overall health benefits and response to therapy?
How can adipose tissue health help explain response variability, sex-specific differences and the heterogeneity of obesity as a disease?
Register for this webinar to learn more about adipose tissue, how it changes during weight loss and with treatment and its relevance within metabolic disease drug development.
Who Should Attend
This webinar will appeal to:
Drug Developers
Clinical Researchers
Clinical Development
Clinical Operations
Clinical Project leaders
Medical/Scientific Leads
Register free on Xtalks: https://xtalks.com/webinars/underneath-the-lost-kilos-adipose-adiposity-and-adiposopathy/
